New drug BT8009 targets Hard-to-Treat cancers in early trial
NCT ID NCT04561362
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have a protein called Nectin-4. The goal is to see if the drug is safe and shrinks tumors. About 329 adults with cancers like bladder, breast, lung, or ovarian cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health
Orlando, Florida, 34747, United States
-
Centre Eugene Marquis
Rennes, 35042, France
-
Centre Leon Berard
Lyon, 69373, France
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, MI, 20133, Italy
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Mary Crowley Cancer Research Center
Dallas, Texas, 75230, United States
-
Next Oncology - Hospital Quironsalud Madrid
Pozuelo de Alarcón, 28223, Spain
-
Ocala Oncology Center
Ocala, Florida, 34474, United States
-
Ospedale San Raffaele
Milan, 20132, Italy
-
START Madrid Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G IZ5, Canada
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.